Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:477

Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review

Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The company undertakes the development and commercialization of small molecular diagnostic products. The company offers different medicine products to improve patient’s health such as pr
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The company undertakes the development and commercialization of small molecular diagnostic products. The company offers different medicine products to improve patient’s health such as predictive medicine, prognostic medicine and personalized medicine products in the areas of oncology and CNS related disorders.

Myriad Genetics, Inc. Key Recent Developments

Feb 05, 2013: Myriad Genetics Reports Revenue Of $149.1m In Q2 Fiscal 2013
Nov 30, 2012: Supreme Court Of United States To Hear Isolated DNA Patent Case
Nov 05, 2012: Myriad Genetics Reports Revenue Of $133.4m In Q1 Fiscal 2013
Aug 16, 2012: US Court of Appeals Upholds Myriad's Gene Patents
Aug 14, 2012: Myriad Genetics Reports Revenue Of $133m In Q4 Fiscal 2012GDPH7218FSA

This comprehensive SWOT profile of Myriad Genetics, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Myriad Genetics, Inc. - Key Facts 5
Myriad Genetics, Inc. - Key Employees 6
Myriad Genetics, Inc. - Key Employee Biographies 7
Myriad Genetics, Inc. - Major Products and Services 8
Myriad Genetics, Inc. - Medical Equipment Pipeline Products Data 9
Myriad Genetics, Inc. Pipeline Products by Equipment Type 9
Myriad Genetics, Inc. Pipeline Products by Development Stage 11
Myriad Genetics, Inc. - History 13
Myriad Genetics, Inc. - Company Statement 18
Myriad Genetics, Inc. - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Section 2 – Company Analysis 22
Myriad Genetics, Inc. - Business Description 22
Myriad Genetics, Inc. - SWOT Analysis 23
SWOT Analysis - Overview 23
Myriad Genetics, Inc. - Strengths 23
Strength - Product Portfolio 23
Strength - Strategic Alliances and Partnerships 23
Strength - Improved Operational Performance 23
Myriad Genetics, Inc. - Weaknesses 24
Weakness - Single Laboratory Facility 24
Weakness - Pending Litigation 24
Myriad Genetics, Inc. - Opportunities 24
Opportunity - Strategic Acquisitions 24
Opportunity - Growing Incidence of Cancer 24
Opportunity - Growing Market Opportunities in Emerging Markets 25
Myriad Genetics, Inc. - Threats 25
Threat - Increasing Competitive Pressures 25
Threat - Uncertain R&D Outcomes 25
Threat - Stringent Government Regulations 25
Myriad Genetics, Inc. - Key Competitors 26
Section 3 – Company Financial Ratios 27
Financial Ratios - Capital Market Ratios 27
Financial Ratios - Annual Ratios 27
Performance Chart 29
Financial Performance 29
Financial Ratios - Interim Ratios 30
Financial Ratios - Ratio Charts 31
Section 4 – Company’s Lifesciences Financial Deals and Alliances 32
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2007 to YTD 2013 32
Myriad Genetics, Inc., Medical Equipment, Deals By Type, 2007 to YTD 2013 33
Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 34
Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 35
Myriad Genetics, Inc., Recent Deals Summary 36
Section 5 – Company’s Recent Developments 37
Myriad Genetics, Inc., Recent Developments 37
Feb 05, 2013: Myriad Genetics Reports Revenue Of $149.1m In Q2 Fiscal 2013 37
Nov 30, 2012: Supreme Court Of United States To Hear Isolated DNA Patent Case 38
Nov 05, 2012: Myriad Genetics Reports Revenue Of $133.4m In Q1 Fiscal 2013 38
Aug 16, 2012: US Court of Appeals Upholds Myriad's Gene Patents 39
Aug 14, 2012: Myriad Genetics Reports Revenue Of $133m In Q4 Fiscal 2012 39
May 16, 2012: Myriad Genetics Announces Presentation Of Lung Cancer Study At American Society For Clinical Oncology Annual Meeting 40
May 01, 2012: Myriad Genetics Reports Revenue Of $129.8m In Q3 Fiscal 2012 40
Mar 29, 2012: Myriad Study Finds High Prevalence Of Mutations In PMS2 Gene 41
Mar 27, 2012: AMP Optimistic In Suit To Invalidate Patents On Breast Cancer Genes 41
Mar 26, 2012: Supreme Court of the United States Remands Gene Patenting Case 42
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Myriad Genetics, Inc., Key Facts 5
Myriad Genetics, Inc., Key Employees 6
Myriad Genetics, Inc., Key Employee Biographies 7
Myriad Genetics, Inc., Major Products and Services 8
Myriad Genetics, Inc. Number of Pipeline Products by Equipment Type 9
Myriad Genetics, Inc. Pipeline Products by Equipment Type 10
Myriad Genetics, Inc. Number of Pipeline Products by Development Stage 11
Myriad Genetics, Inc. Pipeline Products by Development Stage 12
Myriad Genetics, Inc., History 13
Myriad Genetics, Inc., Subsidiaries 20
Myriad Genetics, Inc., Key Competitors 26
Myriad Genetics, Inc., Ratios based on current share price 27
Myriad Genetics, Inc., Annual Ratios 27
Myriad Genetics, Inc., Interim Ratios 30
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2007 to YTD 2013 32
Myriad Genetics, Inc., Medical Equipment, Deals By Type, 2007 to YTD 2013 33
Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 34
Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 35
Myriad Genetics, Inc., Recent Deals Summary 36
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46

List of Figures
Myriad Genetics, Inc. Pipeline Products by Equipment Type 9
Myriad Genetics, Inc. Pipeline Products by Development Stage 11
Myriad Genetics, Inc., Performance Chart (2008 - 2012) 29
Myriad Genetics, Inc., Ratio Charts 31
Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2007 to YTD 2013 32
Myriad Genetics, Inc., Medical Equipment, Deals by Type, 2007 to YTD 2013 33
Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 34
Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 35




...